BioSpace News Archive

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its third quarter 2021 financial results and provide a corporate update on Thursday, November 4, 2021, after the close of the U.S. financial markets.

Brooklyn ImmunoTherapeutics, Inc., a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, announced it will transfer its common stock listing from the NYSE American to the Nasdaq Global Market, effective upon the market close on October 22, 2021.

Dr Robert L. Coleman, Chief Scientific Officer of US Oncology Network and Dr Jacques Mallet, former SVP Portfolio Analytics/Corporate Strategyat Sanofi, join the Company’s Board as independent members.

Hyperfine, Inc. announced the appointment of Michael Brant-Zawadzki, M.D., Fady Charbel, M.D., Murat Gunel, M.D., Brian Litt, M.D., Michael Modic, M.D., Shahid Nimjee, M.D., Roderick Pettigrew, M.D., Michael Schulder, M.D., Eliot Siegel, M.D., and James Smirniotopoulos, M.D., to the Hyperfine Medical Advisory Board.

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2021 financial results on Thursday, October 28, 2021 after the close of the U.S. financial markets.

Movano Inc. (NASDAQ:MOVE), a health technology company designing devices that empower individuals to optimize their health to help prevent and better manage chronic diseases, today announced that it will report third quarter 2021 financial and operating results on Thursday, November 11, 2021.

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), today announced that two abstracts related to the Company’s clinical development programs have been accepted for poster presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® taking place Nov. 12-15, 2021.

Aligos Therapeutics, Inc. today announced upcoming poster presentations highlighting data relating to its chronic hepatitis B (CHB) and nonalcoholic steatohepatitis (NASH) clinical programs at The Liver Meeting® 2021, hosted by the American Association for the Study of Liver Diseases (AASLD), being held virtually November 12 - 15, 2021.

AptarGroup, Inc. today declared a quarterly cash dividend of $0.38 per share. The payment date is November 17, 2021, to stockholders of record as of October 27, 2021.

The gross proceeds to the Company were approximately $134.5 million after deducting the initial purchaser’s discounts and commissions and estimated offering expenses.